Neuroprotective effects of resveratrol in Alzheimer disease pathology

Frontiers in Aging Neuroscience

Volumn 6, Issue AUG, 2014, Pages 1-27

  Rege, Shraddha D ^a   Geetha, Thangiah ^b   Griffin, Gerald D ^c   Broderick, Tom L ^d   Babu, Jeganathan Ramesh ^a  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY AT MONTGOMERY   (United States)

^c TUSKEGEE UNIVERSITY   (United States)

^d MIDWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer disease; Beta amyloid; Neuroprotection; Oxidative stress; Resveratrol

Indexed keywords

AMYLOID BETA PROTEIN; CATHEPSIN; CYCLOOXYGENASE 2; GLUTATHIONE; GLUTATHIONE SYNTHASE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITRIC OXIDE; OXYGEN RADICAL; PICEATANNOL; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; RESVERATROL; TRANSCRIPTION FACTOR NRF2; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN; ENDOTHELIN 1; MEMBRANE METALLOENDOPEPTIDASE; MULTIFUNCTIONAL ENZYME; PROTEINASE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUBILITY; ENCAPSULATION; HUMAN; LIPID PEROXIDATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PLANT; SHORT COURSE THERAPY; WINE; AGE; BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN PERFUSION; BRAIN TISSUE; CONCENTRATION (PARAMETERS); DEGRADATION; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR AMYLOIDOSIS; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 84906266821     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00218     Document Type: Article

References (118)

1. Almeida, L., Vaz-da-Silva, M., Falcão, A., Soares, E., Costa, R., Loureiro, A. I., Fernandes-Lopes, C., Rocha, J.-F., Nunes, T., Wright, L., et al. (2009). Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 53 Suppl 1, S7-15. doi:10.1002/mnfr.200800177
2. Amri, A., Chaumeil, J. C., Sfar, S., and Charrueau, C. (2012). Administration of resveratrol: What formulation solutions to bioavailability limitations? J. Control. Release Off. J. Control. Release Soc. 158, 182-193. doi:10.1016/j.jconrel.2011.09.083.
3. Augustin, M. A., Sanguansri, L., and Lockett, T. (2013). Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Ann. N. Y. Acad. Sci. 1290, 107-112. doi:10.1111/nyas.12130.
4. Bais, A. J., Murphy, P. J., and Dry, I. B. (2000). The molecular regulation of stilbene phytoalexin biosynthesis in Vitis vinifera during grape berry development. Funct. Plant Biol. 27, 425-433.
5. Banks, W. A. (2009). Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 9, S3. doi:10.1186/1471-2377-9-S1-S3.
6. Barnham, K. J., Masters, C. L., and Bush, A. I. (2004). Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3, 205-214. doi:10.1038/nrd1330.
7. Baur, J. A., and Sinclair, D. A. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5, 493-506. doi:10.1038/nrd2060.
8. Bertelli, A. A., Ferrara, F., Diana, G., Fulgenzi, A., Corsi, M., Ponti, W., Ferrero, M. E., and Bertelli, A. (1999). Resveratrol, a natural stilbene in grapes and wine, enhances intraphagocytosis in human promonocytes: a co-factor in antiinflammatory and anticancer chemopreventive activity. Int. J. Tissue React. 21, 93-104.
9. Boocock, D. J., Patel, K. R., Faust, G. E. S., Normolle, D. P., Marczylo, T. H., Crowell, J. A., Brenner, D. E., Booth, T. D., Gescher, A., and Steward, W. P. (2007). Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 848, 182-187. doi:10.1016/j.jchromb.2006.10.017.
10. Burkon, A., and Somoza, V. (2008). Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol. Nutr. Food Res. 52, 549-557. doi:10.1002/mnfr.200700290.
11. Candelario-Jalil, E., de Oliveira, A. C. P., Gräf, S., Bhatia, H. S., Hüll, M., Muñoz, E., and Fiebich, B. L. (2007). Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J. Neuroinflammation 4, 25. doi:10.1186/1742-2094-4-25.
12. Capiralla, H., Vingtdeux, V., Zhao, H., Sankowski, R., Al-Abed, Y., Davies, P., and Marambaud, P. (2012). Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J. Neurochem. 120, 461-472. doi:10.1111/j.1471-4159.2011.07594.x.
13. Carrizzo, A., Forte, M., Damato, A., Trimarco, V., Salzano, F., Bartolo, M., Maciag, A., Puca, A. A., and Vecchione, C. (2013). Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 61, 215-226. doi:10.1016/j.fct.2013.07.021.
14. Chang, J., Rimando, A., Pallas, M., Camins, A., Porquet, D., Reeves, J., Shukitt-Hale, B., Smith, M. A., Joseph, J. A., and Casadesus, G. (2012). Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol. Aging 33, 2062-2071. doi:10.1016/j.neurobiolaging.2011.08.015.
15. Chen, C.-Y., Jang, J.-H., Li, M.-H., and Surh, Y.-J. (2005). Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem. Biophys. Res. Commun. 331, 993-1000. doi:10.1016/j.bbrc.2005.03.237.
16. Chen, R.-S., Wu, P.-L., and Chiou, R. Y.-Y. (2002). Peanut Roots as a Source of Resveratrol. J. Agric. Food Chem. 50, 1665-1667. doi:10.1021/jf011134e.
17. Cho, A. R., Chun, Y. G., Kim, B. K., and Park, D. J. (2014). Preparation of chitosan-TPP microspheres as resveratrol carriers. J. Food Sci. 79, E568-576. doi:10.1111/1750-3841.12395.
18. Clark, D., Tuor, U. I., Thompson, R., Institoris, A., Kulynych, A., Zhang, X., Kinniburgh, D. W., Bari, F., Busija, D. W., and Barber, P. A. (2012). Protection against recurrent stroke with resveratrol: endothelial protection. PloS One 7, e47792. doi:10.1371/journal.pone.0047792.
19. Cottart, C.-H., Nivet-Antoine, V., Laguillier-Morizot, C., and Beaudeux, J.-L. (2010). Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 54, 7-16. doi:10.1002/mnfr.200900437.
20. Creasy, L. L., and Coffee, M. (1988). Phytoalexin production potential of grape berries. J Am Soc Hortic Sci 113, 230-234.
21. Cristòfol, R., Porquet, D., Corpas, R., Coto-Montes, A., Serret, J., Camins, A., Pallàs, M., and Sanfeliu, C. (2012). Neurons from senescence-accelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. J. Pineal Res. 52, 271-281. doi:10.1111/j.1600-079X.2011.00939.x.
22. Csiszár, A., Csiszar, A., Pinto, J. T., Gautam, T., Kleusch, C., Hoffmann, B., Tucsek, Z., Toth, P., Sonntag, W. E., and Ungvari, Z. (2014). Resveratrol Encapsulated in Novel Fusogenic Liposomes Activates Nrf2 and Attenuates Oxidative Stress in Cerebromicrovascular Endothelial Cells From Aged Rats. J. Gerontol. A. Biol. Sci. Med. Sci. doi:10.1093/gerona/glu029.
23. Das, S., and Das, D. K. (2007). Anti-inflammatory responses of resveratrol. Inflamm. Allergy Drug Targets 6, 168-173.
24. Delmas, D., Aires, V., Limagne, E., Dutartre, P., Mazué, F., Ghiringhelli, F., and Latruffe, N. (2011). Transport, stability, and biological activity of resveratrol. Ann. N. Y. Acad. Sci. 1215, 48-59. doi:10.1111/j.1749-6632.2010.05871.x.
25. Faria, A., Pestana, D., Teixeira, D., Azevedo, J., De Freitas, V., Mateus, N., and Calhau, C. (2010). Flavonoid transport across RBE4 cells: A blood-brain barrier model. Cell. Mol. Biol. Lett. 15, 234-241. doi:10.2478/s11658-010-0006-4.
26. Feng, X., Liang, N., Zhu, D., Gao, Q., Peng, L., Dong, H., Yue, Q., Liu, H., Bao, L., Zhang, J., et al. (2013). Resveratrol inhibits β-amyloid-induced neuronal apoptosis through regulation of SIRT1-ROCK1 signaling pathway. PloS One 8, e59888. doi:10.1371/journal.pone.0059888.
27. Floyd, R. A. (1999). Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med. N. Y. N 222, 236-245.
28. Frozza, R. L., Bernardi, A., Hoppe, J. B., Meneghetti, A. B., Matté, A., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., and Salbego, C. (2013). Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules. Mol. Neurobiol. 47, 1066-1080. doi:10.1007/s12035-013-8401-2.
29. Goldberg, D. M., Yan, J., and Soleas, G. J. (2003). Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36, 79-87.
30. Golde, T. E., Estus, S., Younkin, L. H., Selkoe, D. J., and Younkin, S. G. (1992). Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255, 728-730.
31. Granzotto, A., and Zatta, P. (2011). Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Aβ and Aβ-metal complexes toxicity. PloS One 6, e21565. doi:10.1371/journal.pone.0021565.
32. Granzotto, A., and Zatta, P. (2014). Resveratrol and Alzheimer's disease: message in a bottle on red wine and cognition. Front. Aging Neurosci. 6, 95. doi:10.3389/fnagi.2014.00095.
33. Greer, A. K., Madadi, N. R., Bratton, S. M., Eddy, S. D., Mazerska, Z., Hendrickson, H. P., Crooks, P. A., and Radominska-Pandya, A. (2014). Novel resveratrol-based substrates for human hepatic, renal, and intestinal UDP-glucuronosyltransferases. Chem. Res. Toxicol. 27, 536-545. doi:10.1021/tx400408x.
34. Honda, K., Casadesus, G., Petersen, R. B., Perry, G., and Smith, M. A. (2004). Oxidative stress and redox-active iron in Alzheimer's disease. Ann. N. Y. Acad. Sci. 1012, 179-182.
35. Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., Brown, K., Steward, W. P., and Gescher, A. J. (2011). Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. Phila. Pa 4, 1419-1425. doi:10.1158/1940-6207.CAPR-11-0148
36. Huang, T.-C., Lu, K.-T., Wo, Y.-Y. P., Wu, Y.-J., and Yang, Y.-L. (2011). Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PloS One 6, e29102. doi:10.1371/journal.pone.0029102.
37. Hubbard, B. P., and Sinclair, D. A. (2014). Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol. Sci. 35, 146-154. doi:10.1016/j.tips.2013.12.004.
38. Ana I. Romero-Pérez, R. M. L.-R. (1996). Levels of cis- and trans-Resveratrol and Their Glucosides in White and Rosé Vitis vinifera Wines from Spain. J. Agric. Food Chem. - J AGR FOOD CHEM 44. doi:10.1021/jf9507654.
39. Jang, J.-H., and Surh, Y.-J. (2003). Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med. 34, 1100-1110.
40. Jayasena, T., Poljak, A., Smythe, G., Braidy, N., Münch, G., and Sachdev, P. (2013). The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer's disease. Ageing Res. Rev. 12, 867-883. doi:10.1016/j.arr.2013.06.003.
41. Jeandet, P., Bessis, R., and Gautheron, B. (1991). The production of resveratrol (3.5.4'-trihydroxystilbene) by grape berries in different developmental stages. Am. J. Enol Vitic. 42, 41-46.
42. Jeandet, P., Douillet-Breuil, A.-C., Bessis, R., Debord, S., Sbaghi, M., and Adrian, M. (2002). Phytoalexins from the Vitaceae: biosynthesis, phytoalexin gene expression in transgenic plants, antifungal activity, and metabolism. J. Agric. Food Chem. 50, 2731-2741.
43. Johnson, J. J., Nihal, M., Siddiqui, I. A., Scarlett, C. O., Bailey, H. H., Mukhtar, H., and Ahmad, N. (2011). Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 55, 1169-1176. doi:10.1002/mnfr.201100117.
44. Kapetanovic, I. M., Muzzio, M., Huang, Z., Thompson, T. N., and Mc Cormick, D. L. (2011). Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 68, 593-601. doi:10.1007/s00280-010-1525-4.
45. Karuppagounder, S. S., Pinto, J. T., Xu, H., Chen, H.-L., Beal, M. F., and Gibson, G. E. (2009). Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 54, 111-118. doi:10.1016/j.neuint.2008.10.008.
46. Kelsey, N. A., Wilkins, H. M., and Linseman, D. A. (2010). Nutraceutical antioxidants as novel neuroprotective agents. Mol. Basel Switz. 15, 7792-7814. doi:10.3390/molecules15117792.
47. Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007a). SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169-3179. doi:10.1038/sj.emboj.7601758
48. Kim, H. J., Lee, K. W., and Lee, H. J. (2007b). Protective effects of piceatannol against beta626 amyloid-induced neuronal cell death. Ann. N. Y. Acad. Sci. 1095, 473-482. doi:10.1196/annals.1397.051.
49. Kim, Y. A., Lim, S.-Y., Rhee, S.-H., Park, K. Y., Kim, C.-H., Choi, B. T., Lee, S. J., Park, Y.-M., and Choi, Y. H. (2006). Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in beta-amyloid-treated C6 glioma cells. Int. J. Mol. Med. 17, 1069-1075.
50. Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., and Ripova, D. (2012). Structure and pathology of tau protein in Alzheimer disease. Int. J. Alzheimers Dis. 2012, 731526. doi:10.1155/2012/731526.
51. Kris-Etherton, P. M., Hecker, K. D., Bonanome, A., Coval, S. M., Binkoski, A. E., Hilpert, K. F., Griel, A. E., and Etherton, T. D. (2002). Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med. 113 Suppl 9B, 71S-88S.
52. Kumar, A., Naidu, P. S., Seghal, N., and Padi, S. S. V. (2007). Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology 79, 17-26. doi:10.1159/000097511.
53. Lee, M. K., Kang, S. J., Poncz, M., Song, K.-J., and Park, K. S. (2007). Resveratrol protects SH642 SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp. Mol. Med. 39, 376-384. doi:10.1038/emm.2007.42.
54. Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., and Hong, J. T. (2010). Inflammation and Alzheimer's disease. Arch. Pharm. Res. 33, 1539-1556. doi:10.1007/s12272-010-1006-7.
55. Lin, H.-S., and Ho, P. C. (2009). A rapid HPLC method for the quantification of 3,5,4'-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. J. Pharm. Biomed. Anal. 49, 387-392. doi:10.1016/j.jpba.2008.10.042.
56. Lin, Y.-L., Chang, H.-C., Chen, T.-L., Chang, J.-H., Chiu, W.-T., Lin, J.-W., and Chen, R.-M. (2010). Resveratrol protects against oxidized LDL-induced breakage of the blood-brain barrier by lessening disruption of tight junctions and apoptotic insults to mouse cerebrovascular endothelial cells. J. Nutr. 140, 2187-2192. doi:10.3945/jn.110.123505.
57. Liu, B., and Hong, J.-S. (2003). Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304, 1-7. doi:10.1124/jpet.102.035048.
58. Liu, B., Zhang, X., Zhang, W., and Zhen, H. (2007). New enlightenment of French Paradox: resveratrol's potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol. Ther. 6, 1833-1836.
59. Liu, G.-S., Zhang, Z.-S., Yang, B., and He, W. (2012). Resveratrol attenuates oxidative damage and ameliorates cognitive impairment in the brain of senescence-accelerated mice. Life Sci. 91, 872-877. doi:10.1016/j.lfs.2012.08.033
60. Lu, C., Guo, Y., Li, J., Yao, M., Liao, Q., Xie, Z., and Li, X. (2012). Design, synthesis, and evaluation of resveratrol derivatives as Aß1-42 aggregation inhibitors, antioxidants, and neuroprotective agents. Bioorg. Med. Chem. Lett. 22, 7683-7687. doi:10.1016/j.bmcl.2012.09.105.
61. Lu, C., Guo, Y., Yan, J., Luo, Z., Luo, H.-B., Yan, M., Huang, L., and Li, X. (2013). Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer's Disease. J. Med. Chem. 56, 5843-5859. doi:10.1021/jm400567s.
62. Lu, K.-T., Ko, M.-C., Chen, B.-Y., Huang, J.-C., Hsieh, C.-W., Lee, M.-C., Chiou, R. Y. Y., Wung, B.-S., Peng, C.-H., and Yang, Y.-L. (2008). Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem. 56, 6910-6913. doi:10.1021/jf8007212.
63. Lu, X., Ma, L., Ruan, L., Kong, Y., Mou, H., Zhang, Z., Wang, Z., Wang, J. M., and Le, Y. (2010). Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J. Neuroinflammation 7, 46. doi:10.1186/1742-2094-7-46.
64. Marambaud, P., Zhao, H., and Davies, P. (2005). Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 280, 37377-37382. doi:10.1074/jbc.M508246200.
65. Mohar, D. S., and Malik, S. (2012). The Sirtuin System: The Holy Grail of Resveratrol? J. Clin. Exp. Cardiol. 3. doi:10.4172/2155-9880.1000216.
66. Moore, A. H., and O'Banion, M. K. (2002). Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv. Drug Deliv. Rev. 54, 1627-1656.
67. Murakami, K., Irie, K., Ohigashi, H., Hara, H., Nagao, M., Shimizu, T., and Shirasawa, T. (2005). Formation and stabilization model of the 42-mer Abeta radical: implications for the long-lasting oxidative stress in Alzheimer's disease. J. Am. Chem. Soc. 127, 15168- 15174. doi:10.1021/ja054041c.
68. Ono, K., Naiki, H., and Yamada, M. (2006). The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta. Curr. Pharm. Des. 12, 4357-4375.
69. Orallo, F. (2006). Comparative studies of the antioxidant effects of cis- and trans-resveratrol. Curr. Med. Chem. 13, 87-98.
70. Pallàs, M., Porquet, D., Vicente, A., and Sanfeliu, C. (2013). Resveratrol: new avenues for a natural compound in neuroprotection. Curr. Pharm. Des. 19, 6726-6731.
71. Piaceri, I., Nacmias, B., and Sorbi, S. (2013). Genetics of familial and sporadic Alzheimer's disease. Front. Biosci. Elite Ed. 5, 167-177.
72. Porquet, D., Casadesús, G., Bayod, S., Vicente, A., Canudas, A. M., Vilaplana, J., Pelegrí, C., Sanfeliu, C., Camins, A., Pallàs, M., et al. (2013). Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age Dordr. Neth. 35, 1851- 1865. doi:10.1007/s11357-012-9489-4.
73. Prasad, K. (2012). Resveratrol, wine, and atherosclerosis. Int. J. Angiol. Off. Publ. Int. Coll. Angiol. Inc 21, 7-18. doi:10.1055/s-0032-1306417.
74. Quincozes-Santos, A., Bobermin, L. D., Latini, A., Wajner, M., Souza, D. O., Gonçalves, C.-A., and Gottfried, C. (2013). Resveratrol protects C6 astrocyte cell line against hydrogen peroxide-induced oxidative stress through heme oxygenase 1. PloS One 8, e64372. doi:10.1371/journal.pone.0064372.
75. Rege, S. D., Kumar, S., Wilson, D. N., Tamura, L., Geetha, T., Mathews, S. T., Huggins, K. W., Broderick, T. L., and Babu, J. R. (2013). Resveratrol protects the brain of obese mice from oxidative damage. Oxid. Med. Cell. Longev. 2013, 419092. doi:10.1155/2013/419092.
76. Richard, T., Pawlus, A. D., Iglésias, M.-L., Pedrot, E., Waffo-Teguo, P., Mérillon, J.-M., and Monti, J.-P. (2011). Neuroprotective properties of resveratrol and derivatives. Ann. N. Y. Acad. Sci. 1215, 103-108. doi:10.1111/j.1749-6632.2010.05865.x.
77. Rivière, C., Papastamoulis, Y., Fortin, P.-Y., Delchier, N., Andriamanarivo, S., Waffo-Teguo, P., Kapche, G. D. W. F., Amira-Guebalia, H., Delaunay, J.-C., Mérillon, J.-M., et al. (2010). New stilbene dimers against amyloid fibril formation. Bioorg. Med. Chem. Lett. 20, 3441-3443. doi:10.1016/j.bmcl.2009.09.074.
78. Roberson, E. D., and Mucke, L. (2006). 100 years and counting: prospects for defeating Alzheimer's disease. Science 314, 781-784. doi:10.1126/science.1132813.
79. Romano, A. D., Serviddio, G., de Matthaeis, A., Bellanti, F., and Vendemiale, G. (2010). Oxidative stress and aging. J. Nephrol. 23 Suppl 15, S29-36.
80. Romero-Pérez, A. I., Ibern-Gómez, M., Lamuela-Raventós, R. M., and de La Torre-Boronat, M. C. (1999). Piceid, the major resveratrol derivative in grape juices. J. Agric. Food Chem. 47, 1533-1536.
81. Scapagnini, G., Vasto, S., Sonya, V., Abraham, N. G., Nader, A. G., Caruso, C., Calogero, C., Zella, D., and Fabio, G. (2011). Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol. Neurobiol. 44, 192-201. doi:10.1007/s12035-011-8181-5.
82. Selkoe, D. J. (2001). Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimers Dis. JAD 3, 75-80.
83. Selkoe, D. J. (2002). Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J. Clin. Invest. 110, 1375-1381. doi:10.1172/JCI16783.
84. Selkoe, D. J., American College of Physicians, and American Physiological Society (2004). Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med 140, 627-638.
85. Sessa, M., Tsao, R., Liu, R., Ferrari, G., and Donsì, F. (2011). Evaluation of the stability and antioxidant activity of nanoencapsulated resveratrol during in vitro digestion. J. Agric. Food Chem. 59, 12352-12360. doi:10.1021/jf2031346.
86. Sidoryk-Wegrzynowicz, M., Wegrzynowicz, M., Lee, E., Bowman, A. B., and Aschner, M. (2011). Role of astrocytes in brain function and disease. Toxicol. Pathol. 39, 115-123. doi:10.1177/0192623310385254.
87. Simão, F., Matté, A., Pagnussat, A. S., Netto, C. A., and Salbego, C. G. (2012). Resveratrol preconditioning modulates inflammatory response in the rat hippocampus following global cerebral ischemia. Neurochem. Int. 61, 659-665. doi:10.1016/j.neuint.2012.06.009.
88. Singh, C. K., Kumar, A., Lavoie, H. A., Dipette, D. J., and Singh, U. S. (2013). Diabetic complications in pregnancy: is resveratrol a solution? Exp. Biol. Med. Maywood NJ 238, 482-490. doi:10.1177/1535370212473704.
89. Soleas, G. J., Diamandis, E. P., and Goldberg, D. M. (2001). The world of resveratrol. Adv. Exp. Med. Biol. 492, 159-182.
90. Soleas, G. J., Diamandis, E. P., and Goldberg, D. M. (1997). Wine as a biological fluid: History, production, and role in disease prevention. J. Clin. Lab. Anal. 11, 287-313. doi:10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4.
91. Sönmez, U., Sönmez, A., Erbil, G., Tekmen, I., and Baykara, B. (2007). Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci. Lett. 420, 133- 137. doi:10.1016/j.neulet.2007.04.070.
92. Strosznajder, J. B., Czapski, G. A., Adamczyk, A., and Strosznajder, R. P. (2012). Poly(ADP758 ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease. Mol. Neurobiol. 46, 78-84. doi:10.1007/s12035-012-8258-9.
93. Sun, A. Y., Wang, Q., Simonyi, A., and Sun, G. Y. (2008). Botanical phenolics and brain health. Neuromolecular Med. 10, 259-274. doi:10.1007/s12017-008-8052-z.
94. Sun, A. Y., Wang, Q., Simonyi, A., and Sun, G. Y. (2010). Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol. 41, 375-383. doi:10.1007/s12035-010-8111-y.
95. Szekeres, T., Fritzer-Szekeres, M., Saiko, P., and Jäger, W. (2010). Resveratrol and resveratrol analogues--structure-activity relationship. Pharm. Res. 27, 1042-1048. doi:10.1007/s11095-010-0090-1.
96. Tabner, B. J., El-Agnaf, O. M. A., Turnbull, S., German, M. J., Paleologou, K. E., Hayashi, Y., Cooper, L. J., Fullwood, N. J., and Allsop, D. (2005). Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J. Biol. Chem. 280, 35789-35792. doi:10.1074/jbc.C500238200.
97. Takaoka, M. (1940). The Phenolic Substances of White Hellebore (Veratrum Grandiflorum Loes. Fill). V. Nippon Kagaku Kaishi 61, 1067-1069. doi:10.1246/nikkashi1921.61.1067.
98. Tang, B. L., and Chua, C. E. L. (2008). SIRT1 and neuronal diseases. Mol. Aspects Med. 29, 187-200. doi:10.1016/j.mam.2007.02.001.
99. Timmers, S., Auwerx, J., and Schrauwen, P. (2012). The journey of resveratrol from yeast to human. Aging 4, 146-158.
100. Vauzour, D. (2012). Dietary Polyphenols as Modulators of Brain Functions: Biological Actions and Molecular Mechanisms Underpinning Their Beneficial Effects. Oxid. Med. Cell. Longev. 2012, e914273. doi:10.1155/2012/914273.
101. Venturini, C. D., Merlo, S., Souto, A. A., Fernandes, M. da C., Gomez, R., and Rhoden, C. R. (2010). Resveratrol and red wine function as antioxidants in the nervous system without cellular proliferative effects during experimental diabetes. Oxid. Med. Cell. Longev. 3, 434-441.
102. Vingtdeux, V., Dreses-Werringloer, U., Zhao, H., Davies, P., and Marambaud, P. (2008). Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci. 9 Suppl 2, S6. doi:10.1186/1471-2202-9-S2-S6.
103. Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P., Wu, Q., Simon, J. E., Janle, E. M., Lobo, J., Ferruzzi, M. G., Davies, P., et al. (2010). AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 285, 9100-9113. doi:10.1074/jbc.M109.060061.
104. Vrhovšek, U., Eder, R., and Wendelin, S. (1995). The occurrence of trans-resveratrol in Slovenian red and white wines. Acta Aliment. 242, 203-212.
105. Walle, T. (2011). Bioavailability of resveratrol. Ann. N. Y. Acad. Sci. 1215, 9-15. doi:10.1111/j.1749-6632.2010.05842.x.
106. Walle, T., Hsieh, F., De Legge, M. H., Oatis, J. E., Jr, and Walle, U. K. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. Biol. Fate Chem. 32, 1377-1382. doi:10.1124/dmd.104.000885.
107. Wang, H., Yang, Y.-J., Qian, H.-Y., Zhang, Q., Xu, H., and Li, J.-J. (2012). Resveratrol in cardiovascular disease: what is known from current research? Heart Fail. Rev. 17, 437- 448. doi:10.1007/s10741-011-9260-4.
108. Wang, J., Ho, L., Zhao, Z., Seror, I., Humala, N., Dickstein, D. L., Thiyagarajan, M., Percival, S. S., Talcott, S. T., and Pasinetti, G. M. (2006). Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 20, 2313-2320. doi:10.1096/fj.06-6281com.
109. Wang, Q., Xu, J., Rottinghaus, G. E., Simonyi, A., Lubahn, D., Sun, G. Y., and Sun, A. Y. (2002). Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 958, 439-447.
110. Wenzel, E., and Somoza, V. (2005). Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49, 472-481. doi:10.1002/mnfr.200500010.
111. Wimo, A., Winblad, B., Aguero-Torres, H., and von Strauss, E. (2003). The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord. 17, 63-67.
112. Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., and Husemann, J. (2003). Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 9, 453-457. doi:10.1038/nm838.
113. Youdim, K. A., Dobbie, M. S., Kuhnle, G., Proteggente, A. R., Abbott, N. J., and Rice-Evans, C. (2003). Interaction between flavonoids and the blood-brain barrier: in vitro studies. J. Neurochem. 85, 180-192.
114. Yu, C., Shin, Y. G., Chow, A., Li, Y., Kosmeder, J. W., Lee, Y. S., Hirschelman, W. H., Pezzuto, J. M., Mehta, R. G., and van Breemen, R. B. (2002). Human, rat, and mouse metabolism of resveratrol. Pharm. Res. 19, 1907-1914.
115. Zhang, H., Morgan, B., Potter, B. J., Ma, L., Dellsperger, K. C., Ungvari, Z., and Zhang, C. (2010). Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am. J. Physiol. Heart Circ. Physiol. 299, H985-994. doi:10.1152/ajpheart.00489.2010.
116. Zhang, H., Zhang, J., Ungvari, Z., and Zhang, C. (2009). Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 29, 1164-1171. doi:10.1161/ATVBAHA.109.187146.
117. Zhang, Y., Song, H., Shang, Z., Chen, A., Huang, D., Zhao, H., and Du, H. (2014). Amino Acid- PEGylated Resveratrol and Its Influence on Solubility and the Controlled Release Behavior. Biol. Pharm. Bull. 37, 785-793.
118. Zhuang, H., Kim, Y.-S., Koehler, R. C., and Doré, S. (2003). Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann. N. Y. Acad. Sci. 993, 276-286; discussion 287-288.